Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
about
Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activityTadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension.Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activityPhosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells.Tadalafil Promotes the Recovery of Peripheral Neuropathy in Type II Diabetic Mice.Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction.Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL-1 cardiac cell line.Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury.Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway.Regulation of cAMP by phosphodiesterases in erythrocytes.Anticipated classes of new medications and molecular targets for pulmonary arterial hypertensionSildenafil in Infants and ChildrenStrategies in early clinical development for the treatment of basic defects of cystic fibrosis.Treatment with Sildenafil and Donepezil Improves Angiogenesis in Experimentally Induced Critical Limb Ischemia.PDE5 Inhibitor Tadalafil and Hydroxychloroquine Cotreatment Provides Synergistic Protection against Type 2 Diabetes and Myocardial Infarction in Mice.Regulation of injury-induced neurogenesis by nitric oxide.Sildenafil acutely reverses the hypoxic pulmonary vasoconstriction response of the newborn pig.Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).The ability of phosphodiesterase-5 inhibitors sildenafil and ordonafil to reverse L-NAME induced cardiac hypertrophy in the rabbit: possible role of calcineurin and p38.
P2860
Q24323077-06A549EB-A5AC-4960-95FE-E55B1097C274Q34449909-F54D20B6-081C-4BC4-878B-C44299B46419Q34808466-9FE38AA8-DF82-41C1-855A-F01CA9A3CAE7Q35740400-B5BC6439-BDB3-43B7-BC90-437F0EE4E9FCQ36082944-CCEB7CDA-7789-4185-A99D-C70C9812F4F6Q36217672-A1A4CE55-1230-4451-BB9C-E566033D3813Q36293532-EAF037AF-4782-4726-86D4-3D76F7FBCF57Q37190561-2A117F37-1763-4F5E-BB17-A3DBB9750EB2Q37291307-F99F7726-53CC-411A-82B2-2D8A55245FB6Q37772720-3B43FE4F-B80B-4A3C-B116-C64C7005AF03Q38105550-694D842A-20A6-4FEC-B73B-4CBD4E0DDDFDQ38652768-BDBF41D2-2840-4454-A186-41673CC09765Q38733938-8CD2F26C-1070-41CB-A7E3-B0902CBD4730Q41902396-896CE933-252B-4299-8DF3-9B6EB52F0F5AQ41913523-9DD74AEE-B0CB-4132-93D7-E44104D68FFFQ42041084-89912751-11EE-4302-AD19-260B37C66391Q44082011-EB348BC4-D1AF-44D1-BC4E-117A5D034FF1Q53958552-1B1F2578-F864-49BD-AFD4-38D8432454EEQ54489074-73524C5A-2533-4188-85B9-95ED35CEDD90
P2860
Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
@ast
Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
@en
type
label
Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
@ast
Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
@en
prefLabel
Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
@ast
Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
@en
P2860
P356
P1476
Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension.
@en
P2093
Anna R Hemnes
Hunter C Champion
P2860
P304
P356
10.1586/14779072.4.3.293
P577
2006-05-01T00:00:00Z